Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 3/2017

17.08.2017

Use of direct oral anticoagulants in patients on immunomodulatory agents

verfasst von: L. Man, A. Morris, J. Brown, S. Palkimas, K. Davidson

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Immunomodulatory agents (IMiDs) are used to treat multiple hematologic malignancies. Their use is also associated with increased risk of venous thromboembolism (VTE). Direct oral anticoagulants (DOACs) have been increasingly utilized but due to their relative novelty, their role in malignancy has only been recently investigated. The objective of this study was to assess the safety and efficacy of DOACs in patients receiving IMiDs. This was a retrospective study of patients at our institution treated with an IMiD and concomitant warfarin or DOAC between January 1, 2010 and December 31, 2015. Information on demographic and clinical characteristics was collected. Separate encounters were collected for each specific combination of IMiD and anticoagulant. Bleeding and thrombotic events were recorded. There were four bleeding events in the DOAC group; all were non-major. There were six bleeding events in the warfarin group, two of which were major (gastrointestinal bleeding (GIB) and subarachnoid hemorrhage (SAH)) and four of which were non-major. Of the two major bleeds in this group, neither event occurred with concomitant antiplatelet therapy. There was one thrombotic event in the DOAC group, which was a myocardial infarction, suspected to be related to carfilzomib. There were no thrombotic events in the warfarin group. This was a retrospective, single-institution study assessing the safety and efficacy of DOACs as compared to warfarin in patients on IMiDs. DOACs may represent an attractive alternative to warfarin for VTE prophylaxis in patients on IMiDs but prospective studies in this population are warranted.
Literatur
1.
Zurück zum Zitat Silverstein M, Heit J, Mohr D, Petterson T, O’Fallon W, Melton L III (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism. Arch Intern Med 158:585–593CrossRefPubMed Silverstein M, Heit J, Mohr D, Petterson T, O’Fallon W, Melton L III (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism. Arch Intern Med 158:585–593CrossRefPubMed
2.
Zurück zum Zitat Blom JW, Doggen CJM, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293(6):715–722CrossRefPubMed Blom JW, Doggen CJM, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293(6):715–722CrossRefPubMed
3.
Zurück zum Zitat Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24(3):431–436CrossRefPubMed Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24(3):431–436CrossRefPubMed
4.
Zurück zum Zitat Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA et al (2009) Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23:2147–2152CrossRefPubMed Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA et al (2009) Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23:2147–2152CrossRefPubMed
5.
Zurück zum Zitat Cancer-Associated Venous Thromboembolic Disease (2016) In: NCCN Clinical Practice Guidelines for Supportive Care: Cancer-Associated Venous Thromboembolic Disease. VTE-A. NCCN, Washington, DC Cancer-Associated Venous Thromboembolic Disease (2016) In: NCCN Clinical Practice Guidelines for Supportive Care: Cancer-Associated Venous Thromboembolic Disease. VTE-A. NCCN, Washington, DC
6.
Zurück zum Zitat Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414–423CrossRefPubMed Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414–423CrossRefPubMed
7.
Zurück zum Zitat Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z et al (2016) Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol 3026(16):1–9 Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z et al (2016) Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol 3026(16):1–9
8.
Zurück zum Zitat Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146–153CrossRefPubMed Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146–153CrossRefPubMed
9.
Zurück zum Zitat Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Subcommittee on control of anticoagulation of the Scientific and Standardization Committee of the International Society of Thrombosis an. J Thromb Haemost 3(4):692–694CrossRefPubMed Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Subcommittee on control of anticoagulation of the Scientific and Standardization Committee of the International Society of Thrombosis an. J Thromb Haemost 3(4):692–694CrossRefPubMed
10.
Zurück zum Zitat Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK et al (2017) Rivaroxaban or aspirin for extended treatment of venous thromboembolism. NEJM 376(13):1211–1222CrossRefPubMed Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK et al (2017) Rivaroxaban or aspirin for extended treatment of venous thromboembolism. NEJM 376(13):1211–1222CrossRefPubMed
Metadaten
Titel
Use of direct oral anticoagulants in patients on immunomodulatory agents
verfasst von
L. Man
A. Morris
J. Brown
S. Palkimas
K. Davidson
Publikationsdatum
17.08.2017
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 3/2017
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-017-1534-9

Weitere Artikel der Ausgabe 3/2017

Journal of Thrombosis and Thrombolysis 3/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.